Introduction
Colorectal cancer is the third most common malignant cancer in men; it is also the second most common form of cancer in women and the second most common type of life-threatening cancer worldwide. 1 The major methods for the treatment of cancer include surgery, chemotherapy, radiation therapy, and palliative care.2 Among them, chemotherapy is widely used to control tumor growth or to relieve symptoms after surgery.3 However, treatment with the majority of current chemotherapeutic agents is generally associated with severe side effects including cardiotoxicity, hepatotoxicity, neurotoxicity, immunosuppression, and myelosuppression.4-6 Hence, the identification of more effective and/or less toxic anticancer agents would improve the management of colorectal cancer.
The progression of cancer is characteristically linked to resistance to apoptosis, an active process of programmed cell death. Apoptosis has been characterized as a fundamental cellular activity that maintains the physiological balance of the organism. 7, 8 Accumulating evidence has demonstrated that the induction of apoptosis in tumor cells has been shown to be the most common anticancer mechanism conjoint with many cancer therapies. In general, apoptosis may be initiated through two major pathways: the extrinsic [death receptor (DR)-mediated] pathway and the intrinsic (mitochondrial-mediated) pathway that involves the activation of caspases.9,10 The products of several genes have been demonstrated to be critical in the regulation of these two pathways, including caspase cascades, Bcl-2, and inhibitor of apoptosis protein (IAP) family members. In the extrinsic pathway, the binding of extracellular death ligands to their cell-surface DRs leads to the activation of caspase-8. By contrast, the intrinsic pathway is activated by the release of proapoptotic factors, such as cytochrome c from the mitochondria to the cytosol, following loss of inner mitochondrial membrane integrity and activation of caspase-9. Moreover, the extrinsic pathway can crosstalk to the intrinsic pathway through the caspase-8-mediated cleavage of Bid, a member of the Bcl-2 family of proteins, which ultimately amplify the intrinsic apoptotic pathway.11,12 Therefore, agents that target the apoptosis pathway without affecting normal cells play crucial roles as potential drug targets in cancer treatment.
For thousands of years, herbal medicines have been used with apparent safety and efficacy for alleviating and treating various diseases in Asia, including Korea, China, and Japan. Typical traditional Korean medicinal prescriptions consist of more than four components that are mixed to minimize side effects, maximize medical effects, and improve quality of life. Among them, Dae-Hwang-Mok-Dan-Tang (DHMDT) is an aqueous polyherbal formulation, which consists of crude ingredients extracted from five herbs, that has been known to exert antidiarrhea and anti-inflammatory activities. DHMDT has been used to treat patients with digestive tract cancers in traditional Korean medicine.13 However, despite its valuable clinical effects for patients, little is known about the molecular biochemical basis of the effects of DHMDT. As a part of our search for novel biologically active substances for the prevention and treatment of cancers from traditional medicinal resources, we evaluated whether DHMDT could inhibit the growth of and trigger apoptosis in human colon cancer HCT-116 cells.
Materials

Preparation of the DHMDT extract
DHMDT, which is composed of five medicinal plants (Table 1) , was obtained from Dongeui Oriental Hospital, Dongeui University College of Oriental Medicine (Busan, Republic of Korea). Each of the five herbs in DHMDT was cut into small pieces and then mixed together to obtain a total amount of 42 g in the ratios shown Table 1 . The mixture was boiled with distilled water (42 g/500 mL) for 3 hours. The extract was filtered with a 0.45-mM filter to remove insoluble materials, and the filtrate was lyophilized and then crushed into a thin powder. The extracts were dissolved to a 100 mg/mL concentration with distilled water, and the stock solution was then diluted with medium to the desired concentration prior to use.
Cell culture and cell viability assay
The colon cancer HCT-116 cell and Chang liver (an immortalized nontumor cell line derived from normal liver tissue) cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained at 37 • C in 5% CO 2 in Dulbecco's modified Eagle's medium (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum, and 1% penicillin/streptomycin (Gibco-BRL). The cell viability assay was performed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In brief, the cells were treated with different concentrations of DHMDT. After treatments for the indicated times, 0.5 mg/mL of MTT (Sigma-Aldrich Chemicals, St. Louis, MO, USA) solution was added, followed by incubation for 2 hours at 37 • C in the dark; then, the medium was removed. The formazan precipitate was dissolved in dimethyl sulfoxide (Sigma-Aldrich). Absorbance of the formazan product was measured at 540 nm with an enzyme-linked immunosorbent assay reader (Molecular Devices, Sunnyvale, CA, USA). N-BenzyloxycarbonylVal-Ala-Asp-fluoromethylketone (z-VAD-fmk), a pan-caspase inhibitor, and LY294002, a selective inhibitor of phosphatidylinositol 3-kinase (PI3K), were obtained from Calbiochem (San Diego, CA, USA) and Cell Signaling Technology, Inc. (Danvers, MA, USA), respectively. For the morphological study, the cells were photographed directly using an inverted microscope (Carl Zeiss, Oberkochen, Germany).
Nuclear staining with 4,6-diamidino-2-phenyllindile
For the assessment of apoptosis, the cells were washed with phosphate-buffered saline (PBS) and fixed with 3.7% paraformaldehyde (Sigma-Aldrich) in PBS for 10 minutes at room temperature. The fixed cells were washed with PBS and stained with 2.5 g/mL of 4,6-diamidino-2-phenyllindile (Sigma-Aldrich) solution for 10 minutes at room temperature. The cells were washed twice with PBS, and the stained nuclei were analyzed using a fluorescence microscope (Carl Zeiss).
2.4.
Agarose gel electrophoresis for DNA fragmentation assay After DHMDT treatment, the cells were lysed in a buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM trypsine-ethylene diamine tetraacetic acid (EDTA), and 0.5% Triton X-100 for 1 hour on ice. The lysates were vortexed and cleared by centrifugation at 19,000 g for 30 minutes at 4 • C. An equal volume of neutral phenol/chloroform/isoamyl alcohol (25:24:1, v/v/v; Sigma-Aldrich) was used for DNA extraction in the supernatant, followed by electrophoretic analysis on 1.5% agarose gels containing 0.1 g/mL ethidium bromide (EtBr; Sigma-Aldrich). The DNA size marker (100 bp ladder) was purchased from Bioneer Corp. (Daejeon, Republic of Korea).
DNA flow cytometric detection of apoptosis
After treatment with DHMDT, the cells were harvested, washed twice with ice-cold PBS, and fixed with 75% ethanol at 4 • C for 30 min; the DNA content of the cells was stained using a DNA staining kit (CycleTEST PLUS Kit; Becton Dickinson, San Jose, CA, USA) with propidium iodide (PI). The DNA content at the sub-G1 phases was then determined using a FACSCalibur flow cytometer and analyzed using Cell Quest software (Becton Dickinson 
In vitro caspase activity assay
The activities of the caspases were determined using colorimetric assay kits (R&D Systems), which utilize synthetic tetrapeptides [Asp-Glu-Val-Asp (DEAD) for caspase-3; Ile-GluThr-Asp (IETD) for caspase-8; and Leu-Glu-His-Asp (LEHD) for caspase-9] labeled with p-nitroaniline (pNA) that is linked to the end of the caspase-specific substrate. Briefly, the DHMDTtreated cells and the untreated cells were lysed in the supplied lysis buffer. The supernatants were collected and incubated with the supplied reaction buffer containing dithiothreitol and DEAD-pNA, IETD-pNA, or LEHD-pNA as substrates at 37 • C for 2 hours in the dark. The reactions were measured by changes in absorbance at 405 nm using an enzyme-linked immunosorbent assay reader.
Measurement of mitochondrial membrane potential ( m)
The mitochondrial membrane potential (MMP) values were determined using the dual-emission potentialsensitive probe, 5,5 ,6,6 -tetrachloro-1,1 ,3,3 -tetraethylimidacarbocyanine iodide (JC-1; Sigma-Aldrich), which is internalized and concentrated by respiring mitochondria and, therefore, can reflect MMP changes in live cells. Briefly, the cells were collected and incubated with 10 M of JC-1 for 30 minutes at 37 • C in the dark. After JC-1 was removed, the cells were washed with PBS to remove unbound dye, and the amount of JC-1 retained by 10,000 cells per sample was measured at 488 nm and 575 nm using a flow cytometer.
Statistical analysis
The data are reported as the mean ± standard deviation of three independent experiments. A one-way analysis of variance was performed to determine statistical significance. Significant differences were established at p < 0.05.
Results
DHMDT inhibited cell viability in HCT-116 cells
To investigate the effects of DHMDT on HCT-116 cell growth, the cells were treated with various concentrations of DHMDT, and the MTT assay was carried out after incubation for the indicated times. As shown in Fig. 1A , DHMDT inhibited the cell viability of HCT-116 cells in a concentration-and time-dependent manner. For example, the cell viability was inhibited by more than 47% or 68% in the cells exposed to 0.8 mg/mL or 1.0 mg/mL of DHMDT for 72 hours, respectively, as compared to the untreated controls. In addition, visual inspection using inverted microscopy revealed that treatment with DHMDT resulted in numerous morphological changes, including extensive cytosolic vacuolization and the appearance of irregular cell membrane buds (Fig. 1B) . The results of an additional experiment using Chang liver cells, conducted to examine the effect of DHMDT on the proliferation of normal cells, are shown in Fig. 1C . The MTT assay results indicated that DHMDT concentrations up to 1.0 mg/mL did not induce cytotoxicity. Therefore, the highest concentration of DHMDT in HCT-116 colon cancer cells was selected as 1 mg/mL.
DHMDT induced apoptosis in HCT-116 cells
To answer the question of whether growth inhibition by DHMDT was associated with the induction of apoptosis, we examined apoptotic features by measuring the chromatin condensation of the nuclei, DNA fragmentation, and the amount of sub-G1 phase and annexin V-positive cells.
As shown in Fig. 2A , treatment with DHMDT resulted in the observation of a significant number of cells with chromatin condensation and the formation of apoptotic bodies in a concentration-dependent manner, whereas these features were not observed in the control cells. Treatment with DHMDT induced progressive accumulation of fragmented DNA, which appeared as a typical ladder pattern of DNA fragmentation in a concentration-dependent manner (Fig. 2B ). In addition, treatment with DHMDT resulted in the increased accumulation of cells in the apoptotic hypodiploid sub-G1 phase and an increase in the number of annexin V-positive cells ( Fig. 2C and  D) . Taken together, these results revealed that the cytotoxic effects observed in response to DHMDT are associated with the induction of apoptosis in HCT-116 cells.
DHMDT modulated the expression of apoptosis-related genes in HCT-116 cells
In order to determine which apoptosis pathway contributes to DHMDT-induced apoptosis, the levels of DR and corresponding proapoptotic ligands were first examined by Western blot analyses. After DHMDT treatment, the protein levels of DR4, DR5, and Fas were not altered; however, the expression of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) increased in a concentrationdependent manner (Fig. 3) . Next, we examined the effects of DHMDT on the levels of the IAP family proteins. The results of Western blotting showed that DHMDT treatment resulted in a concentration-dependent decrease in the expression levels of XIAP and survivin but not cIAP-1 and cIAP-2 (Fig. 3). 
DHMDT induced activation of caspases and cleavage of poly(ADP-ribose)-polymerase and phospholipase C-1 in HCT-116 cells
We then examined the expression levels and activities of caspases during DHMDT-induced HCT-116 cell apoptosis. As shown in Fig. 4A , Western blot analyses revealed that the expression levels of pro-caspase-3 in cells treated with DHMDT were concentration-dependently downregulated and the expression levels of active-caspase-3 were upregulated. Moreover, although the active forms of caspase-8 and caspase-9 were not observed, the levels of the proforms of caspase-8 and caspase-9, initiator caspases of extrinsic and intrinsic apoptosis pathways, respectively, were downregulated. Under the same conditions, the in vitro activities of the caspases were also measured using colorimetric substrates specific for each caspase, and we found that DHMDT stimulated caspase-3, caspase-8, and caspase-9 activities in a dose-dependent manner (Fig. 4B) . In addition, DHMDT treatment led to progressive proteolytic cleavage of poly(ADP-ribose)-polymerase (PARP) and phospholipase C-␥1 (PLC-␥1) proteins (Fig. 4A) .
DHMDT induced caspase-dependent apoptosis in HCT-116 cells
To further confirm the involvement of DHMDT-induced activation of caspases, the cells were pretreated with or without Z-VAD-fmk, a pan-caspase inhibitor, for 1 hour, followed by treatment with DHMDT. The results indicated that pretreatment with Z-VAD-fmk resulted in significant prevention of the appearance of cells with apoptotic features, such as chromatin condensation and formation of apoptotic bodies, and attenuation of the progressive accumulation of fragmented DNA following treatment with DHMDT ( Fig. 5A and B) . Furthermore, z-DEVD-fmk also decreased the accumulation of annexin V-FITC stained cells and increased cell viability in the presence of DHMDT (Fig. 5C and D) . These results provide evidence of DHMDT-induced apoptotic cell death in association with activation of caspases in HCT-116 cells.
DHMDT truncated Bid and induced the mitochondrial translocation of Bax and the loss of MMP in HCT-116 cells
To further confirm the DHMDT-induced apoptotic pathway, this study examined the effects of DHMDT on the levels of Bcl-2 family proteins and cytochrome c, as well as the MMP values. As shown in Fig. 6A , the total levels of proapoptotic Bax and antiapoptotic Bcl-2 proteins remained unchanged in response to DHMDT treatment; however, DHMDT treatment decreased the cytosolic levels of Bax, whereas its mitochondrial levels significantly increased after treatment with increasing concentrations of DHMDT (Fig. 6C) . Subsequent Western blot analyses revealed progressive downregulation of total Bid protein and accumulation of truncated Bid (tBid) as well as a marked decrease in mitochondrial cytochrome c and a concurrent increase in cytosolic cytochrome c (Fig. 6C) . Moreover, DHMDT treatment caused a concentration-dependent loss of MMP in comparison to the untreated control (Fig. 6B) . These results suggest that DHMDT inserts Bax from the cytosol into the mitochondria inducing loss of MMP, thereby resulting in mitochondrial dysfunction, release of cytochrome c to the cytosol, and apoptosis induction.
DHMDT inactivated the PI3K/Akt pathway in HCT-116 cells
Because the PI3K/Akt pathway is the most important signaling pathway in both cell growth and in the survival of many cancers, we determined whether DHMDT-induced apoptosis in HCT-116 cells is involved in this pathway by determining the expression and phosphorylation levels of PI3K and Akt, a downstream effector of PI3K, after treatment with DHMDT. As shown in Fig. 7A , the levels of phosphorylated PI3K and Akt proteins were time-dependently decreased after DHMDT treatment, and they completely disappeared after 48 h; however, the total expression levels of phosphorylated PI3K and the Akt remained the same throughout the experiment. Next, to evaluate the relationship between PI3K/Akt activity and apoptosis, we investigated whether DHMDT significantly induces apoptosis in the presence of LY290042, a specific inhibitor of PI3K. As shown in Fig. 7B-D 
Discussion
In this study, we investigated whether DHMDT induces apoptosis in HCT-116 cells and sought to identify the mechanisms related to cell death. Our findings demonstrated that DHMDT could time-and concentration-dependently inhibit cell viability and induce apoptosis as measured by chromatin condensation of the nuclei, DNA fragmentation and induction of the sub-G1 phase and annexin V-stained cells, all of which are the hallmark features of apoptosis. It was also suggested that DHMDT stimulates caspase-dependent extrinsic and intrinsic apoptosis pathways in HCT-116 cells. Furthermore, we investigated the linkage between the PI3K/Akt pathway and apoptosis induction, and our results showed that DHMDT increased apoptosis through the inactivation of the PI3K/Akt pathway. Apoptosis is the rigorous, active, and orderly process of cell death, and dysregulated apoptosis is considered to induce a number of pathological conditions, including cancer. Therefore, the induction of apoptosis is an important target for cancer therapy. 7, 8 In the present study, we examined various aspects of the mechanisms of apoptosis induction by DHMDT in human colon cancer HCT-116 cells, and we found that DHMDT activated both initiator caspases (caspase-8 and caspase-9) of the extrinsic and intrinsic pathways, and downstream effector caspase-3 (Fig. 4) , which was associated with the degradation of PARP and PLC-␥1; these are hallmarks of apoptosis and substrates of activated caspase.15,16 Although the levels of DRs, such as DR4, DR5, and Fas, remained unchanged after DHMDT treatment, DHMDT considerably increased the levels of their ligands, including TRAIL and FasL. DHMDT also partially downregulated the IAP family proteins, such as XIAP and survivin, which reportedly block apoptosis because of their function as direct inhibitors by binding to several caspases and inhibiting them (Fig. 3) . However, blocking caspase activity by pretreating the cells with z-DEVD-fmk, a pan-caspase inhibitor, significantly attenuated DHMDT-induced apoptosis and growth inhibition (Fig. 5) . Therefore, the data support that DHMDT-induced apoptosis in HCT-116 cells is caspase-dependent, and both the intrinsic and the extrinsic pathways are activated by DHMDT.
In addition, although DHMDT did not affect the total expression levels of proapoptotic Bax or antiapoptotic Bcl-2 in HCT-116 cells, DHMDT treatment resulted in a concentrationdependent increase in the mitochondrial levels of Bax with a concomitant decrease in the cytoplasmic Bax levels. The present data also clearly revealed that DHMDT treatment resulted in a dose-dependent loss of MMP and an increase in the release of cytochrome c from the mitochondria to the cytosol (Fig. 6 ) with a decline in intact Bid occurring concurrently with a pronounced increase of tBid. Because the release of cytochrome c requires mitochondrial membrane insertion and oligomerization of Bax,17,18 the translocation of Bax proteins from the cytosol to the mitochondria represents a key event for the activation of the intrinsic pathway. Moreover, caspase-8 connects to the intrinsic pathway via conversion of Bid to form tBid that can translocate to the mitochondrial membrane, where it cooperates with Bax proteins. This cooperation enhances mitochondrial dysfunction, which results in the formation of membrane pores and allows the release of cytochrome c to the cytosol, followed by activation of caspase-9.17,19 Therefore, our data indicated that DHMDT induces Bid truncation and Bax translocation to the mitochondria from the cytosol, leading to the release of cytochrome c by enhancing mitochondrial dysfunction, and finally induction of apoptosis in HCT-116 cells.
By contrast, it was identified that the PI3K/Akt pathway is a well-characterized cell survival signaling pathway, and it blocks apoptosis in a variety of cell types. Notably, the deregulation of the PI3K/Akt pathway is associated with resistance to chemotherapeutic agents,20,21 and the aberrant activation of this pathway is implicated in the initiation and progression of several types of human malignancies, including lung cancer.22,23 Therefore, a number of studies have noted that the proapoptotic potential of some anticancer agents is highly correlated with the inactivation of PI3K/Akt pathway, [24] [25] [26] [27] [28] indicating that the inhibition of the PI3K/Akt signaling cascade can serve as an effective strategy for the treatment of cancers.
Therefore, we further investigated whether the inactivation of the PI3K/Akt pathway is necessary for DHMDT-induced apoptosis, and we found that levels (but not the total levels) of phosphorylated PI3K and Akt were markedly decreased in DHMDT-treated HCT-116 cells (Fig. 7A) . In addition, cotreatment with DHMDT and LY294002, a PI3K inhibitor, markedly increased apoptosis and decreased cell viability (Fig. 7B-E) , indicating that PI3K/Akt might play a survival role in DHMDTinduced HCT-116 cell apoptosis.
In summary, the results of this study demonstrate that DHMDT triggers apoptosis of human colon cancer HCT-116 cells through activation of the intrinsic caspase pathway along with the DR-mediated extrinsic pathway, and activation of caspases is responsible for the mediation of DHMDT-induced apoptosis. Moreover, the inhibition of the PI3K/Akt pathway may play an important role in DHMDT-induced apoptosis in HCT-116 cells. Although the results of this study provide new information on the possible mechanisms for the anticancer activity of DHMDT, further studies are needed to identify the active compounds.
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